Polypeptide linker for preparing multispecific antibodies

LAG-3 binding members

Tunable Chimeric Antigen Receptors

Antibody drug conjugate platform using bispecific antibody

HETERODIMERIC ANTIGEN BINDING PROTEINS

Anti-DR5 antibodies and methods of use thereof

Anti-MET antibodies and uses thereof

Treatment of disease responsive to modulation of cannabanoid 1(CB1) receptor signaling

Selective sulfonation of benzodiazepine derivatives

RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME

Fc mutants with improved functional activity

Antigen binding constructs to CD3

J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use

Methods for producing fabs and IgG bispecific antibodies

Compositions and methods related to engineered Fc constructs

Heterodimeric immunoglobulin constructs and preparation methods thereof

Humanized or chimeric CD3 antibodies

Tau-binding antibodies

POLYPEPTIDE VARIANTS AND USES THEREOF

Recombinant polypeptide production methods

Compositions and methods for making antibodies based on use of an expression-enhancing locus

ADAPTIVE CHIMERIC ANTIGEN RECEPTOR T-CELL DESIGN

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies

Binding molecules binding PD-L1 and LAG-3

Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs

Drug regulated transgene expression

Heavy chain only antibodies to ANG-2

Antibodies specific for CD70 and their uses

Compositions and methods related to engineered Fc constructs

Triple vector for expressing antibody molecules in full therapeutic format

Bispecific antigen binding construct

NOVEL ANTIBODY FORMAT

Immunoglobulin constant region Fc receptor binding agents

IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same

HC-CDR3-only libraries with reduced combinatorial redundancy and optimized loop length distribution

Methods for producing Fabs and bi-specific antibodies

BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR

Human CD3 binding antibody

EFFECTOR-DEFICIENT ANTI-CD32A ANTIBODIES

ANTIBODY CONSTANT REGION VARIANT

ENGINEERED HETERODIMERIC PROTEIN DOMAINS

Heterodimeric antibodies that bind CD3 and tumor antigens

ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF

Genetically-modified cells and method for producing same

EGFR binding molecules

BI-SPECIFIC AGENTS

Cysteine-optimized stradomers

ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)

Use of FCRN antagonists for treatment of generalized myasthenia gravis

STABILIZATION OF FC-CONTAINING POLYPEPTIDES

PRODUCTION OF HETEROMULTIMERIC PROTEINS

Compositions and methods for inhibiting T cell exhaustion

Monovalent Asymmetric Tandem Fab Bispecific Antibodies

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Anti-polyubiquitin multispecific antibodies

Constructs having a SIRP-alpha domain or variant thereof

Heterodimeric immunoglobulins

Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide

Cytosol-penetrating antibody and use thereof

ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF

Fc-region variants with improved protein A-binding

Multispecific antibody platform and related methods

Anti-glyco-MUC1 antibodies and their uses

Anti-neuropilin antigen-binding proteins and methods of use thereof

Protease-activated T cell bispecific molecules

MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF

Anti-CD3 antibodies and methods of use

Anti-CD38 antibodies and methods of use

Heterodimeric proteins and methods for producing and purifying them

Cysteine engineered antibody drug conjugates

Method of treating osteoarthritis with human oncostatin M antibodies

LAG-3-binding molecules and methods of use thereof

Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Engineered immunoglobulins with altered FcRn binding

Methods of treatment of CD123 overexpressing disorders

Antibodies against CD73 and uses thereof

POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS

ANTIBODIES AGAINST CD73 AND USES THEREOF

Multispecific NK engager protein

Bispecific antibody platform

Multispecific NK engager protein

Engineered antibody Fc variants for enhanced serum half life

METHODS OF SCREENING FOR MULTISPECIFIC ANTIBODIES

T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES

ASPGR ANTIBODIES AND USES THEREOF

Readily isolated bispecific antibodies with native immunoglobulin format

Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Bispecific antibodies having constant region mutations and uses therefor

Anti-CD3 antibodies and methods of use

Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains

Antibodies with Altered Binding to FcRn and Methods of Using Same

METHOD OF MANUFACTURING BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES

Humanized monoclonal antibody specific to syndecan-1

Bispecific T cell activating antigen binding molecules

Bispecific T cell activating antigen binding molecules

Caninized human antibodies to human IL-4R alpha

TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY

Multispecific antibodies that target HIV GP120 and CD3

Heterodimer molecule based on CH3 domain, and preparation method and use thereof

IL2R common gamma chain antibodies

Means and methods for treating HBV infection and associated conditions

IG1 AND THE THERAPEUTIC USE THEREOF

Production of T cell retargeting hetero-dimeric immunoglobulins

Variable regions for NKp46 binding proteins

Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations

Anti-variant Fc-region antibodies and method of use

Method for producing antibody CH3 domain heterodimeric mutant pair using yeast mating and CH3 mutant pair produced thereby

Human monoclonal anti-PD-L1 antibodies and methods of use

PD-L1-BINDING AGENTS AND USES THEREOF

Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide

GARP-TGF-beta 1 antibodies

Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof

Bispecific antibodies specifically binding to PD1 and LAG3

Protein complex by use of a specific site of an immunoglobulin fragment for linkage

ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION

Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof

Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Method For Making Heteromultimeric Molecules

Methods for producing fabs and bi-specific antibodies

Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

HIDE1 COMPOSITIONS AND METHODS

PROCESSES FOR PURIFYING PROTEINS FROM PLASMA

Combination therapy for the treatment of cancer

Heterodimeric antibodies that bind CD3 and tumor antigens

PRODUCTION OF HETEROMULTIMERIC PROTEINS

Bispecific antigen-binding constructs targeting Her2

Heavy chain constant regions with reduced binding to Fc gamma receptors

ANTI-CD3XROB04 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereof

Antigen-binding constructs targeting HER2

CD3 binding polypeptides

Core constructs and their uses in configuring pharmaceutical molecules

Fusion immunomodulatory proteins and methods for making same

Cytotoxicity-inducing therapeutic agent

Non-human animals that select for light chain variable regions that bind antigen

Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding

Dual PDGF/VEGF antagonists

Tetra-specific, octameric binding agents and antibodies against toxin A and toxin B for treatment of infection

CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof

Method for expansion of a population of cells with IL2R beta/common gamma chain antibodies

Human CD3 binding antibody

Compositions and methods of use for treating metabolic disorders

Multispecific binding molecules having specificity to dystroglycan and laminin-2

Heterodimeric antibodies that bind CD3 and tumor antigens

Bispecific T cell activating antigen binding molecules

Bispecific T cell activating antigen binding molecules

Monoclonal antibodies against HER2

Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

IL-2R beta/common gamma chain antibodies

Selective sulfonation of benzodiazepine derivatives

BISPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD FOR ISOLATION OF SUCH

Tau-binding antibodies

IgM- or IgE-Modified Binding Proteins and Uses Thereof

Stable heterodimeric antibody design with mutations in the Fc domain

IL2Rbeta/common gamma chain antibodies

Monoclonal antibodies against HER2

Drug-conjugated bi-specific antigen-binding constructs

Immunoglobulin constant region Fc receptor binding agents

Nucleic acids encoding artificial signal peptides and methods of production thereof

Bispecific antigen-binding constructs targeting HER2

MONOCLONAL ANTIBODIES AGAINST HER2

Serpin fusion polypeptides and methods of use thereof

FcRn antagonists and methods of use

Conjugated compounds comprising cysteine-engineered antibodies

Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

ALK4.ActRIIB heteromultimers

Assembly of bispecific antibodies

Fc variants with altered binding to FcRn

Fc VARIANTS WITH ALTERED BINDING TO FcRn

POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS

Long-acting insulin or insulin analogue conjugate

BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF

Methods of glycoprotein analysis

Modified stem cells and uses thereof

Anti-transferrin receptor antibodies and methods of use

Antibodies against CD73 and uses thereof

Internalizing moieties for treatment of cancer

Anti-CHIKV monoclonal antibodies directed against the E2 structural protein

Recombinant Cell Surface Capture Proteins

Bispecific checkpoint inhibitor antibodies

ASPGR antibodies and uses thereof

Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof

Bispecific multivalent fusion proteins

Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer

IL15/IL15Rα heterodimeric Fc-fusion proteins

OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF

Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Use

Hetero-Dimeric Immunoglobulins

Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use

BISPECIFIC ANTIBODY MOLECULE

Method for producing polypeptide hetero-oligomer

Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use

Multivalent and multiepitopic antibodies having agonistic activity and methods of use

MASKED ANTI-CD3 ANTIBODIES AND METHODS OF USE

Multispecific antibodies facilitating selective light chain pairing

Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof

Polymeric Fc proteins and methods of screening to alter their functional characteristics

Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15Ra and therapeutic uses thereof

Engineered polypeptides and uses thereof

Crystal structures of heterodimeric Fc domains

Fc mutants with modified functional activity

Use of HLA-B27 homodimers for cancer treatment

Bispecific anti-HER2 antibody

Antigen binding complex having agonistic activity and methods of use

Bispecific binding proteins and uses thereof

RECEPTOR-TARGETED NANOPARTICLES FOR ENHANCED TRANSCYTOSIS MEDIATED DRUG DELIVERY

Domain-exchanged antibody

Stable heterodimeric antibody design with mutations in the Fc domain

Binding molecules directed against influenza hemagglutinin and uses thereof

IgG bispecific antibodies and processes for preparation

Method and compositions for cellular immunotherapy

Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies

Modulation of antigen immunogenicity by deleting epitopes recognized by NKT cells

Methods and means for the production of Ig-like molecules

BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3

BISPECIFIC ANTIBODIES AGAINST HER2

MONOMERIC FC DOMAINS

CS1 targeted chimeric antigen receptor-modified T cells

Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases

Modified glycoproteins

METHODS TO MODULATE LYSINE VARIANT DISTRIBUTION

Fc-region variants with modified FcRn- and protein A-binding properties

Fc-region variants with modified FcRn-binding and methods of use

Asymmetric multispecific antibodies

Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains

BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES

Bak binding proteins

Chimeric antigen receptors (CAR) to selectively target protein complexes

Methods and means for the production of Ig-like molecules

Rodent bispecific heterodimeric proteins

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Trispecific and/or trivalent binding proteins

MONOCLONAL ANTIBODIES AGAINST C-MET

Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies

BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES

MONOCLONAL ANTIBODIES AGAINST C-MET

BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 FOR USE IN THE TREATMENT OF OVARIAN CANCER

Bispecific antibodies against CD3ϵ and BCMA

Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof

Anti-C5 antibodies having improved pharmacokinetics

Methods of modifying antibodies for purification of bispecific antibodies

POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS

Transgene genetic tags and methods of use

MULTIVALENT ANTIGEN-BINDING PROTEINS

Production of heteromultimeric proteins using mammalian cells

Antibodies against CD73

Soluble engineered monomeric Fc

Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

Heterodimeric antibody Fc-containing proteins and methods for production thereof

BCMA CHIMERIC ANTIGEN RECEPTORS

Immunoglobulins and variants directed against pathogenic microbes

MONOVALENT BINDING PROTEINS

Genetic engineering of non-human animals for the production of chimeric antibodies

PSMA and CD3 bispecific T cell engaging antibody constructs

Bispecific T cell engaging antibody constructs

BCMA and CD3 bispecific T cell engaging antibody constructs

Immunoglobulin constant region Fc receptor binding agents

CONSTANT REGION ANTIBODY FUSION PROTEINS AND COMPOSITIONS THEREOF

Multispecific antigen binding proteins

Antibodies that bind human cannabinoid 1 (CB1) receptor

Modified antigen binding polypeptide constructs and uses thereof

Anti-CD3 antibodies and methods of use

Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens

Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

Multi-chain polypeptide-containing tri-specific binding molecules

Genetic engineering of non-human animals for the production of chimeric antibodies

Genetic engineering of non-human animals for the production of chimeric antibodies

Genetic engineering of non-human animals for the production of chimeric antibodies

Genetic engineering of non-human animals for the production of chimeric antibodies

Antibodies and conjugates thereof

Genetic engineering of non-human animals for the production of chimeric antibodies

Genetic engineering of non-human animals for the production of chimeric antibodies

Genetic engineering of non-human animals for the production of chimeric antibodies

Bi-and monospecific, asymmetric antibodies and methods of generating the same

Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein

Anti-FGFR1c antibody-FGF21 fusion proteins

Antibodies for epidermal growth factor receptor 3 (HER3)

Antibody variants composition

Recombinant monovalent antibodies

Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof

Lytic-peptide-Her2/neu (Human Epidermal growth factor Receptor 2) ligand conjugates and methods of use

Anti-inflammatory molecules with tissue-targeting functions

Antigen binding proteins to oncostatin M (OSM)

Drug regulated transgene expression

TETRAVALENT MULTISPECIFIC ANTIBODIES

Production of T cell retargeting hetero-dimeric immunoglobulins

Method of treating idiopathic pulmonary fibrosis by administering human oncostatin M antibodies

ENGINEERED HETERODIMERIC PROTEIN DOMAINS

MULTISPECIFIC ANTIBODIES

Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses

Antibody/drug conjugates and methods of use

MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF

Anti-CD28 humanized antibodies

TEM8 ANTIBODIES AND METHODS OF USE

Heavy chain only antibodies to ANG-2